top of page

Podcast

Sep 17, 2025

Making data surveillance a reality with Tanya du Plessis

In this episode of Clinical Data Talks, Sylvain Berthelot welcomes Tanya Du Plessis, Chief Data Strategist and Solutions Officer at Bioforum. Together, they unpack what data surveillance really means and how to make it a practical reality in today’s clinical trials.

With over two decades of experience in clinical data management, Tanya shares how the evolving regulatory landscape – including ICH E8 and ICH E6(R3) –  is pushing sponsors to adopt a more holistic, risk-based view of data. Rather than reacting to problems at the end of a study, she explains how data surveillance empowers teams to identify risks earlier, address root causes, and protect trial integrity.

Sylvain and Tanya discuss why regulators intentionally avoid a rigid definition of data surveillance, how cross-functional collaboration between statisticians, medics, and data managers is key, and why proactive strategies ultimately save both time and cost. 

Tune in to explore how data surveillance is reshaping the role of data managers, the culture of oversight, and the future of trial success.

placeholder_white_300x300.jpg

Share via

See CRScube in action

Explore how our platform will elevate your team and clinical trial management.

crscube_in_action_ca.avif

Get insights straight to your inbox

img_001.avif

Explore our knowledge base

Stay in-the-know with regular updates and industry opinions from our expert team.

Featured resources

icon_01.png

Electronic safety reporting in clinical trials: What sponsors need to know

For sponsors and CROs, it is crucial to understand the implications of the full enforcement of ICH E2B(R3) standards, especially as it impacts both pre- and post-authorization submissions.

icon_01.png

From our sales leaders Juan Munoz-Pujol and Scott Robertson

icon_01.png

Why ICH E2B(R3) still matters in 2026 – A conversation with Ducksang (David) Im

While E2B(R3) standard has existed for some time, global adoption has been gradual. What makes 2026 critical is that many regulatory authorities worldwide have now finalized mandatory transitions.

bottom of page